Since October 1, GPs in New Zealand can prescribe Viekira Pak and Viekira Pak-RBV (with Ribavirin). Viekira Pak is a DAA (Direct-Acting Antiviral) which has cure rates of 90+ per cent, fewer side effects and a shorter treatment duration compared to previous treatment. Viekira Pak is funded for people with hepatitis C genotype 1a or 1b of the virus.
Harvoni was also funded in New Zealand in 2016. This DAA is funded for people with decompensation (liver failure) through a specialist.